Repare Therapeutics Inc (RPTX)
3.25
-0.01
(-0.31%)
USD |
NASDAQ |
Nov 14, 16:00
3.24
-0.01
(-0.31%)
After-Hours: 20:00
Repare Therapeutics Enterprise Value: -41.27M for Nov. 14, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 14, 2024 | -41.27M |
| November 13, 2024 | -40.85M |
| November 12, 2024 | -30.86M |
| November 11, 2024 | -22.14M |
| November 08, 2024 | -26.82M |
| November 07, 2024 | -31.07M |
| November 06, 2024 | -25.97M |
| November 05, 2024 | -13.64M |
| November 04, 2024 | -27.24M |
| November 01, 2024 | -27.24M |
| October 31, 2024 | -37.02M |
| October 30, 2024 | -32.77M |
| October 29, 2024 | -26.82M |
| October 28, 2024 | -23.84M |
| October 25, 2024 | -31.49M |
| October 24, 2024 | -36.17M |
| October 23, 2024 | -33.62M |
| October 22, 2024 | -29.79M |
| October 21, 2024 | -26.39M |
| October 18, 2024 | -33.62M |
| October 17, 2024 | -37.02M |
| October 16, 2024 | -34.05M |
| October 15, 2024 | -36.60M |
| October 14, 2024 | -35.32M |
| October 11, 2024 | -45.95M |
| Date | Value |
|---|---|
| October 10, 2024 | -40.42M |
| October 09, 2024 | -38.72M |
| October 08, 2024 | -32.77M |
| October 07, 2024 | -32.77M |
| October 04, 2024 | -20.02M |
| October 03, 2024 | -32.34M |
| October 02, 2024 | -32.77M |
| October 01, 2024 | -31.92M |
| September 30, 2024 | -33.20M |
| September 27, 2024 | -62.11M |
| September 26, 2024 | -59.56M |
| September 25, 2024 | -64.66M |
| September 24, 2024 | -65.08M |
| September 23, 2024 | -64.66M |
| September 20, 2024 | -58.71M |
| September 19, 2024 | -59.56M |
| September 18, 2024 | -67.20M |
| September 17, 2024 | -68.48M |
| September 16, 2024 | -67.20M |
| September 13, 2024 | -58.29M |
| September 12, 2024 | -80.79M |
| September 11, 2024 | -88.85M |
| September 10, 2024 | -86.30M |
| September 09, 2024 | -87.58M |
| September 06, 2024 | -88.43M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-114.42M
Minimum
Oct 30 2023
1.307B
Maximum
Jan 07 2021
347.12M
Average
232.44M
Median
Sep 22 2023
Enterprise Value Benchmarks
| Aurinia Pharmaceuticals Inc | 843.94M |
| Edesa Biotech Inc | 5.103M |
| Lexaria Bioscience Corp | 26.69M |
| InMed Pharmaceuticals Inc | 61.20M |
| Xenon Pharmaceuticals Inc | 2.442B |
Enterprise Value Related Metrics
| Net Income (Quarterly) | -34.41M |
| Total Expenses (Quarterly) | 34.84M |
| EPS Diluted (Quarterly) | -0.81 |
| Earnings Yield | -61.54% |
| Normalized Earnings Yield | -50.45 |